UNSPSC 51401558: Loprazolam

This classification denotes a benzodiazepine with the molecular formula C23H21ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 759N8462G8, chemically known as 6-(2-chlorophenyl)-2,4-dihydro-2-((4-methyl-1-piperazinyl)methylene)-8-nitro-1h-imidazo(1,2-a) (1,4)benzodiazepin-1-one but generally known as loprazolam, which bears US NIH Compound Identifier 3033860. European Medicines Agency schedules Loprazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08576MIG.

UNSPSC 51401558 Loprazolam, a Commodity code, nominally designates a specific pharmaceutical product; however, the recent state and local contracting activity under this code shows a substantial mismatch. Seminole County, Florida's solicitation tagged to this code seeks procurement of naloxone (an opioid antagonist used in overdose reversal) and safe drug deactivation systems—neither of which corresponds to loprazolam, a benzodiazepine sedative. The issuing body is a county government purchasing department conducting a competitive procurement through an IFB notice. The scope includes annual supply of 1,900 units of naloxone and 800 drug deactivation systems with quarterly deliveries to a county health facility, along with standard compliance requirements such as E-Verify certification, drug-free workplace attestation, workers' compensation and general liability insurance, and a three-month probationary termination clause.

The code shows minimal recent activity aligned with its nominal scope. Seminole County posted the naloxone and drug deactivation systems IFB (IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023—a historical date inconsistent with the posting date, indicating a data quality issue in the source record. The procurement is potentially FEMA-funded and specifies no explicit set-aside designations. Geographic coverage is limited to Florida based on available records. The mismatch between the commodity code (loprazolam) and the actual procurement (naloxone and deactivation systems) suggests either a tagging error in the state and local procurement system or a wholesale substitution of solicitation scope post-posting. For vendors pursuing this code, confirmation of current active opportunities under the correct pharmaceutical or drug-management classification is advisable.